公开(公告)号：US12121526B2

公开(公告)日：2024-10-22

申请号：US17128955

申请日：2020-12-21

申请人： University of Maryland, Baltimore ,  The United States of America as Represented by the Department of Veterans Affairs

发明人： J. Marc Simard

IPC分类号： A61K31/64 ,  A61K31/57 ,  A61P9/10 ,  G01N33/68 ,  A61K31/427 ,  A61K31/565 ,  A61K38/00

CPC分类号： A61K31/57 ,  A61K31/64 ,  A61P9/10 ,  G01N33/6872 ,  A61K31/427 ,  A61K31/565 ,  A61K38/00

摘要： The present invention concerns protection of an organ or tissue outside of the central nervous system following an ischemic episode. In particular aspects, the invention concerns organ preservation for transplantation, angina pectoris, kidney reperfusion injury, and so forth. In specific embodiments, the organ is subjected to an inhibitor of an NCCa-ATP channel that is regulated by SUR1. Exemplary inhibitors include sulfonylurea compounds, such as glibenclamide, for example.

公开(公告)号：US12115169B2

公开(公告)日：2024-10-15

申请号：US18432492

申请日：2024-02-05

申请人： Marinus Pharmaceuticals, Inc.

发明人： Joseph Hulihan ,  Alex Aimetti ,  Scott Braunstein

IPC分类号： A61K31/57 ,  A61K31/00 ,  A61P25/08

CPC分类号： A61K31/57 ,  A61K31/658 ,  A61P25/08

摘要： The disclosure to methods for treating tuberous sclerosis complex and epilepsy disorders comprising administering to a subject in need thereof a therapeutically effective amount of ganaxolone or a pharmaceutically acceptable salt thereof.

公开(公告)号：US12109201B2

公开(公告)日：2024-10-08

申请号：US17843028

申请日：2022-06-17

申请人： Ovid Therapeutics, Inc.

发明人： Matthew During

IPC分类号： A61K31/437 ,  A61K9/00 ,  A61K31/165 ,  A61K31/19 ,  A61K31/195 ,  A61K31/197 ,  A61K31/27 ,  A61K31/325 ,  A61K31/36 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/4192 ,  A61K31/423 ,  A61K31/433 ,  A61K31/44 ,  A61K31/444 ,  A61K31/4535 ,  A61K31/513 ,  A61K31/515 ,  A61K31/53 ,  A61K31/55 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/57 ,  A61K31/7048 ,  A61K45/06

CPC分类号： A61K31/437 ,  A61K9/0019 ,  A61K31/165 ,  A61K31/19 ,  A61K31/195 ,  A61K31/197 ,  A61K31/27 ,  A61K31/325 ,  A61K31/36 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/4192 ,  A61K31/423 ,  A61K31/433 ,  A61K31/44 ,  A61K31/444 ,  A61K31/4535 ,  A61K31/513 ,  A61K31/515 ,  A61K31/53 ,  A61K31/55 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/57 ,  A61K31/7048 ,  A61K45/06 ,  A61K31/437 ,  A61K2300/00 ,  A61K31/57 ,  A61K2300/00 ,  A61K31/5517 ,  A61K2300/00 ,  A61K31/5513 ,  A61K2300/00 ,  A61K31/44 ,  A61K31/04 ,  A61K2300/00 ,  A61K2300/00 ,  A61K31/27 ,  A61K2300/00 ,  A61K31/433 ,  A61K2300/00 ,  A61K31/55 ,  A61K2300/00 ,  A61K31/4015 ,  A61K2300/00 ,  A61K31/195 ,  A61K2300/00 ,  A61K31/165 ,  A61K2300/00 ,  A61K31/53 ,  A61K2300/00 ,  A61K31/444 ,  A61K2300/00 ,  A61K31/515 ,  A61K2300/00 ,  A61K31/4166 ,  A61K2300/00 ,  A61K31/4192 ,  A61K2300/00 ,  A61K31/19 ,  A61K2300/00 ,  A61K31/513 ,  A61K2300/00 ,  A61K31/36 ,  A61K2300/00 ,  A61K31/4535 ,  A61K2300/00 ,  A61K31/7048 ,  A61K2300/00 ,  A61K31/197 ,  A61K2300/00 ,  A61K31/423 ,  A61K2300/00 ,  A61K31/136 ,  A61K2300/00

摘要： Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.

公开(公告)号：US20240315959A1

公开(公告)日：2024-09-26

申请号：US18605521

申请日：2024-03-14

申请人： Chemo Research, S.L.

发明人： Enrico COLLI ,  Carlos DÍEZ FUERTES

IPC分类号： A61K9/00 ,  A61K31/565 ,  A61K31/57 ,  A61K47/32 ,  A61K47/34

CPC分类号： A61K9/0039 ,  A61K31/565 ,  A61K31/57 ,  A61K47/32 ,  A61K47/34

摘要： The present invention relates to a method for providing contraception in a female subject, comprising continuous intravaginal administration of levonorgestrel of from about 60 μg/day to about 100 μg/day. The invention further relates to a method for treating endometriosis, endometriosis associated pelvic pain (EAPP) and/or dysmenorrhea comprising continuously administering about 60 μg/day to about 160 μg/day of levonorgestrel. Delivery devices, such as, intravaginal rings for putting the methods in practice are also envisaged.

公开(公告)号：US20240299415A1

公开(公告)日：2024-09-12

申请号：US18549968

申请日：2021-12-01

申请人： Shenzhen Evergreen Therapeutics Co., Ltd

发明人： Tao Tom Du ,  Tao Hu ,  Xin Du

IPC分类号： A61K31/57 ,  A61K31/573 ,  A61P11/00

CPC分类号： A61K31/57 ,  A61K31/573 ,  A61P11/00

摘要： A treatment method for interstitial pneumonia by means of hydroxyprogesterone caproate alone or in combination with other drugs, and corresponding pharmaceutical uses, and pharmaceutical compositions. Hydroxyprogesterone caproate can reduce pulmonary inflammation and fibrosis symptoms, reduce pulmonary collagen deposition, and reduce the levels of various inflammatory factors in bronchoalveolar lavage fluid and plasma. Hydroxyprogesterone caproate combined with dexamethasone can improve lipid metabolism abnormalities caused by dexamethasone treatment alone.

公开(公告)号：US12083130B2

公开(公告)日：2024-09-10

申请号：US17255927

申请日：2020-10-01

申请人： Caren Pharmaceuticals, Inc.

发明人： Arnold Edward Friedman ,  Rebecca L. Glaser

IPC分类号： A61K31/57 ,  A61K31/4196 ,  A61K31/473 ,  A61K31/568 ,  A61K31/573 ,  A61K31/593 ,  A61P25/28

CPC分类号： A61K31/57 ,  A61K31/4196 ,  A61K31/473 ,  A61K31/568 ,  A61K31/573 ,  A61K31/593 ,  A61P25/28

摘要： Disclosed herein are compositions and methods useful for the treatment or amelioration of various diseases, disorders, or conditions. Some aspects pertain to a composition comprising a testosterone source, an aromatase inhibitor, and an estriol source. Also presented herein is the surprising discovery that exposing a subject to the compositions disclosed herein can increase a subject's longevity, survival time, life span, and health span, as well as treat Alzheimer's disease.

公开(公告)号：US20240285650A1

公开(公告)日：2024-08-29

申请号：US18496122

申请日：2023-10-27

申请人： ReveraGen BioPharma, Inc.

发明人： John M. MCCALL ,  Eric HOFFMAN ,  Kanneboyina NAGARAJU

IPC分类号： A61K31/573 ,  A61K31/57 ,  A61K31/575 ,  A61P1/04 ,  A61P1/16 ,  A61P3/00 ,  C07J5/00

CPC分类号： A61K31/573 ,  A61K31/57 ,  A61K31/575 ,  A61P1/04 ,  A61P1/16 ,  A61P3/00 ,  C07J5/0038 ,  C07J5/0053 ,  C07J5/0076 ,  Y02A50/30

摘要： The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-κB for the treatment or prevention of muscular wasting disease, including muscular dystrophy.

公开(公告)号：US20240277615A1

公开(公告)日：2024-08-22

申请号：US18568879

申请日：2022-06-09

申请人： Universidade Da Beira Interior

发明人： Adriana OLIVEIRA DOS SANTOS ,  Mariana CARVALHO FERNANDES ,  Patrícia Sofia CABRAL PIRES ,  Gilberto LOURENÇO ALVES ,  Ana Carolina MARICOTO FAZENDEIRO ,  Francisca MATOS SILVA PEREIRA NINA ,  Maria De Fátima DA SILVA FERREIRA GOMES ,  Lina Isabel ESTEVES RODRIGUES

IPC分类号： A61K9/107 ,  A61K8/06 ,  A61K8/37 ,  A61K8/41 ,  A61K31/22 ,  A61K31/366 ,  A61K31/40 ,  A61K31/405 ,  A61K31/4166 ,  A61K31/47 ,  A61K31/505 ,  A61K31/57 ,  A61K31/675 ,  A61K47/14 ,  A61K47/18 ,  A61Q19/00

CPC分类号： A61K9/107 ,  A61K8/06 ,  A61K8/375 ,  A61K8/416 ,  A61K31/22 ,  A61K31/366 ,  A61K31/40 ,  A61K31/405 ,  A61K31/4166 ,  A61K31/47 ,  A61K31/505 ,  A61K31/57 ,  A61K31/675 ,  A61K47/14 ,  A61K47/186 ,  A61Q19/00 ,  A61K2800/10

摘要： The present disclosure relates to a self-emulsifying composition and/or a stable and homogeneous aqueous oil-in-water emulsion comprising a neutral hydrophilic surfactant and a combination of at least two hydrophobic excipients selected from the following list: glycerol monooleate, miglyol 812; propylene glycol monocaprylate; wherein 90% of the droplets comprise a size of less than 180 nm; and wherein the size of 50% of the droplets ranges from 90-120 nm. A pharmaceutical composition comprising said emulsion is also described.

公开(公告)号：US20240252647A1

公开(公告)日：2024-08-01

申请号：US18456612

申请日：2023-08-28

申请人： Journey Medical Corporation

发明人： Dov Tamarkin ,  Elana Gazal ,  Yohan Hazot ,  David Schuz ,  Irakliy Papiashvili

IPC分类号： A61K47/44 ,  A61K8/31 ,  A61K8/34 ,  A61K8/36 ,  A61K9/00 ,  A61K9/12 ,  A61K31/137 ,  A61K31/192 ,  A61K31/4164 ,  A61K31/57 ,  A61K31/573 ,  A61K31/593 ,  A61K31/65 ,  A61K45/06 ,  A61K47/02 ,  A61K47/06 ,  A61K47/10 ,  A61K47/12 ,  A61K47/24 ,  A61Q17/04 ,  A61Q19/00 ,  A61Q19/10

CPC分类号： A61K47/44 ,  A61K8/31 ,  A61K8/342 ,  A61K8/361 ,  A61K9/0014 ,  A61K9/0048 ,  A61K9/12 ,  A61K9/122 ,  A61K9/124 ,  A61K31/137 ,  A61K31/192 ,  A61K31/4164 ,  A61K31/57 ,  A61K31/573 ,  A61K31/593 ,  A61K31/65 ,  A61K45/06 ,  A61K47/02 ,  A61K47/06 ,  A61K47/10 ,  A61K47/12 ,  A61K47/24 ,  A61Q17/04 ,  A61Q19/00 ,  A61Q19/10 ,  A61K2800/31 ,  A61K2800/33

摘要： The present disclosure relates generally to compositions for cosmetic or pharmaceutical application. The compositions include a carrier and rheology modulators.APP

公开(公告)号：US20240252348A1

公开(公告)日：2024-08-01

申请号：US18410155

申请日：2024-01-11

申请人： JUNIPER PHARMACEUTICALS, INC. N/K/A CATALENT JNP, INC.

发明人： Bridget Martell ,  David Friend ,  Martin Doorbar ,  Shen Luk

IPC分类号： A61F6/08 ,  A61K9/00 ,  A61K31/565 ,  A61K31/57 ,  A61K47/32 ,  A61L31/04 ,  A61L31/16

CPC分类号： A61F6/08 ,  A61K9/0036 ,  A61K31/565 ,  A61K31/57 ,  A61K47/32 ,  A61L31/048 ,  A61L31/16 ,  A61L2300/43

摘要： Disclosed herein are segmented EVA Rings that contain progesterone that can be used to prevent preterm birth in subjects with a shortened cervix or to treat luteal phase deficiency or as luteal phase support.